For the treatment of metastatic HER2-positive breast cancer in people who had received two or more prior anti-HER2 regimens, at least one of which was for metastatic cancer, the FDA approved margetuximab-cmkb (MARGENZA, MacroGenics) in combination with chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.